Circulating DNA as biomarker in breast cancer.

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®. PLoS One (2016) 0.79

Liquid biopsies for surveillance and monitoring treatment response of bladder cancer. Ann Transl Med (2016) 0.76

Biology and Biomarkers for Wound Healing. Plast Reconstr Surg (2016) 0.76

Neoadjuvant therapy for treatment of breast cancer: the way forward, or simply a convenient option for patients? Gland Surg (2017) 0.75

Detection of Methylated Circulating DNA as Noninvasive Biomarkers for Breast Cancer Diagnosis. J Breast Cancer (2017) 0.75

Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer. Oncotarget (2017) 0.75

A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound. Sci Rep (2017) 0.75

The correlation between DNMT1 and ERα expression and the methylation status of ERα, and its clinical significance in breast cancer. Oncol Lett (2016) 0.75

Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer. Cancers (Basel) (2017) 0.75

Early Diagnosis of Breast Cancer. Sensors (Basel) (2017) 0.75

Evaluation of p16(INK4α) Hypermethylation from Liquid-based Pap Test Samples in Vietnamese Population. Iran J Public Health (2017) 0.75

Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22

Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36

Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45

Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76

Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59

About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta (2001) 2.18

Circulating tumor cells and circulating tumor DNA. Annu Rev Med (2011) 2.16

Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res (2014) 2.00

Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol (2006) 1.73

Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71

Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62

Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res (1999) 1.55

Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle (2006) 1.54

Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res (2011) 1.32

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol (2014) 1.31

Circulating nucleic acids in cancer and pregnancy. Methods (2010) 1.22

Maspin: molecular mechanisms and therapeutic implications. Cancer Metastasis Rev (2012) 1.21

Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer (2009) 1.20

Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett (2006) 1.11

The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer (2009) 1.09

Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res (2013) 1.09

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med (2015) 1.09

Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clin Exp Immunol (1992) 1.03

Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br J Cancer (1999) 1.03

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer (2011) 1.02

The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res (2014) 0.97

Isolation and comparative study of cell-free nucleic acids from human urine. Ann N Y Acad Sci (2006) 0.96

Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat (2011) 0.95

Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem (2012) 0.95

Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer (2012) 0.94

Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res (2013) 0.94

TP53 gene mutations in plasma DNA of cancer patients. Genes Chromosomes Cancer (1999) 0.94

Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol Biosyst (2011) 0.92

Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls. Epigenetics (2012) 0.92

PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat (2015) 0.91

SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem (2012) 0.91

Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumour Biol (2010) 0.91

Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat (2014) 0.91

Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer. Medicine (Baltimore) (2015) 0.88

Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol Rep (2014) 0.88

DNA methylation markers for early detection of women's cancer: promise and challenges. Epigenomics (2014) 0.87

The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. Br J Cancer (2011) 0.84

Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology (2012) 0.84

ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer (2014) 0.82

Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy. Clin Chim Acta (2013) 0.81

Diagnostic relevance of plasma DNA and DNA integrity for breast cancer. Tumour Biol (2013) 0.80

Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin. Cancer Lett (2013) 0.80

Estrogen receptor alpha (ERα) promoter methylation status in tumor and serum DNA in Egyptian breast cancer patients. Gene (2014) 0.78

The plasma DNA concentration as a potential breast cancer screening marker. Indian J Clin Biochem (2013) 0.77